===
EQS-News: Eckert & Ziegler SE / Key word(s): Quarterly / Interim Statement/Quarter Results
Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
2024-05-14 / 07:50 CET/CEST
The issuer is solely responsible for the content of this announcement.
1st Quarter 2024:
. Sales of EUR 67.6 million (previous year: EUR 57.9 million)
. EBIT before special items of EUR 15.0 million (previous year: EUR 10.6 million)
. Net income EUR 8.5 million (previous year: EUR 4.7 million)
Forecast FY 2024:
. Sales of just under EUR 265 Mio. (confirmed)
. EBIT before special items of around EUR 50 million (confirmed)
Berlin, 14 May 2024. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased sales by 17% to EUR 67.6 million in
the first quarter of 2024 compared to the same period of the previous year. EBIT before special items from continuing
operations (adjusted EBIT) rose by around EUR 4.4 million to EUR 15.0 million. Net profit (from continuing and discontinued
operations) increased by 79% and reached EUR 8.5 million or EUR 0.41 per share.
In the first three months of the year, sales in the Medical segment were around EUR 10.4 million or 43% higher than in
the previous year at EUR 34.6 million. The main growth driver continues to be the business with pharmaceutical
radioisotopes, while sales from plant engineering also increased significantly.
The Isotope Products segment generated external sales of EUR 33.1 million, which was EUR 0.7 million or around 2% lower
than in the first three months of 2023. Compared to the same period of the previous year, there were shifts between the
product groups towards higher-margin products.
The forecast for the 2024 financial year published on March 22, 2024, remains unchanged. The Executive Board continues
to expect sales of just under EUR 265 million and EBIT (earnings before interest and taxes) from continuing operations
before special items of around EUR 50 million.
The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz124e.pdf
About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear
medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical
industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN
DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

2024-05-14 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Eckert & Ziegler SE 

Robert-Rössle-Str.10
13125 Berlin
Germany

Phone:        +49 30 941084-138 
Fax:          +49 30 941084-0 
Internet:     www.ezag.de 
ISIN:         DE0005659700 
WKN:          565970 
Indices:      SDAX, TecDax, 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1901867

End of News EQS News Service
===
1901867 2024-05-14 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1901867&application_name=news

END) Dow Jones Newswires

May 14, 2024 01:50 ET (05:50 GMT)